Concepedia

Stéphanie Braillard

SB

Statistics

Publications

16

Citations

579

H-Index

15

Active since

2007

Affiliations

Drugs for Neglected Diseases Initiative(Current)

University of Antwerp

London School of Hygiene & Tropical Medicine

University of London

University of Auckland

Stéphanie Braillard is an author at Drugs for Neglected Diseases Initiative specializing in antileishmanial treatment, drug discovery, and pharmacology.

ORCID

Publications per year

2007–2023

16

Publications

16

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Charles E. Mowbray, Stéphanie Braillard, Paul A. Glossop et al. · Journal of Medicinal Chemistry · 2021 · 69 citations · Full text

, , +14

Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity

Charles E. Mowbray, Stéphanie Braillard, William C. Speed et al. · Journal of Medicinal Chemistry · 2015 · 67 citations

, , +16

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis

Katrien Van Bocxlaer, Diana Caridha, Chad Black et al. · International Journal for Parasitology Drugs and Drug Resistance · 2019 · 67 citations · Full text

, , +17

7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-<i>b</i>][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis

Andrew M. Thompson, P. D. T. O’Connor, Andrew J. Marshall et al. · Journal of Medicinal Chemistry · 2017 · 58 citations · Full text

, , +13

In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series

Magali Van den Kerkhof, Dorien Mabille, Eric Chatelain et al. · International Journal for Parasitology Drugs and Drug Resistance · 2018 · 52 citations · Full text

, , +17

1–5 of 16